Invention Grant
- Patent Title: (2S,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxmethyl-2-methylpentanoic acid
-
Application No.: US15229398Application Date: 2016-08-05
-
Publication No.: US09670143B2Publication Date: 2017-06-06
- Inventor: Adam D. Hughes , Erik Fenster , Melissa Fleury , Anne-Marie Beausoleil , Venkat R. Thalladi , Jerry Nzerem , Miroslav Rapta
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Wendy Petka
- Main IPC: C07C235/74
- IPC: C07C235/74
Abstract:
In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
Public/Granted literature
Information query
